PL2295417T3 - Nowe produkty pośrednie przydatne do wytwarzania związku alfa-(n-sulfonamido)acetamidu - Google Patents

Nowe produkty pośrednie przydatne do wytwarzania związku alfa-(n-sulfonamido)acetamidu

Info

Publication number
PL2295417T3
PL2295417T3 PL10190591T PL10190591T PL2295417T3 PL 2295417 T3 PL2295417 T3 PL 2295417T3 PL 10190591 T PL10190591 T PL 10190591T PL 10190591 T PL10190591 T PL 10190591T PL 2295417 T3 PL2295417 T3 PL 2295417T3
Authority
PL
Poland
Prior art keywords
sulfonamido
novel intermediates
intermediates useful
acetamide compound
preparing alpha
Prior art date
Application number
PL10190591T
Other languages
English (en)
Inventor
Jr John E Starrett;
Kevin W Gillman
Richard E Olson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2295417(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PL2295417T3 publication Critical patent/PL2295417T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL10190591T 2007-10-31 2008-10-14 Nowe produkty pośrednie przydatne do wytwarzania związku alfa-(n-sulfonamido)acetamidu PL2295417T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31
EP10190591A EP2295417B1 (en) 2007-10-31 2008-10-14 Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound
EP08843687A EP2205575B1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Publications (1)

Publication Number Publication Date
PL2295417T3 true PL2295417T3 (pl) 2012-11-30

Family

ID=40193955

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08843687T PL2205575T3 (pl) 2007-10-31 2008-10-14 Nowy związek alfa-(N-sulfonamido) acetamidowy jako inhibitor wytwarzania peptydu beta-amyloidu
PL10190591T PL2295417T3 (pl) 2007-10-31 2008-10-14 Nowe produkty pośrednie przydatne do wytwarzania związku alfa-(n-sulfonamido)acetamidu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08843687T PL2205575T3 (pl) 2007-10-31 2008-10-14 Nowy związek alfa-(N-sulfonamido) acetamidowy jako inhibitor wytwarzania peptydu beta-amyloidu

Country Status (28)

Country Link
US (2) US8084477B2 (pl)
EP (3) EP2295417B1 (pl)
JP (1) JP5460605B2 (pl)
KR (1) KR20100075575A (pl)
CN (2) CN102718689A (pl)
AR (1) AR069135A1 (pl)
AT (1) ATE502022T1 (pl)
AU (1) AU2008319122A1 (pl)
BR (1) BRPI0818837A2 (pl)
CA (1) CA2704360A1 (pl)
CL (1) CL2008003271A1 (pl)
CO (1) CO6270332A2 (pl)
CY (2) CY1112337T1 (pl)
DE (1) DE602008005636D1 (pl)
DK (2) DK2205575T3 (pl)
EA (2) EA016447B1 (pl)
ES (2) ES2390042T3 (pl)
HR (2) HRP20110219T1 (pl)
IL (1) IL205406A0 (pl)
MX (1) MX2010004319A (pl)
NZ (1) NZ584545A (pl)
PE (1) PE20091394A1 (pl)
PL (2) PL2205575T3 (pl)
PT (2) PT2295417E (pl)
SG (2) SG174043A1 (pl)
SI (2) SI2295417T1 (pl)
TW (1) TW200927099A (pl)
WO (1) WO2009058552A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ533603A (en) 2001-12-20 2007-02-23 Bristol Myers Squibb Co Alpha-(N-sulphonamido)acetamide derivatives as beta-amyloid inhibitors used for treating Alzheimer's Disease and Down's syndrome
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
KR20110133046A (ko) * 2009-03-19 2011-12-09 브리스톨-마이어스 스큅 컴퍼니 베타 아밀로이드 펩티드 생성의 억제제로서의 신규 알파-(ｎ-술폰아미도)아세트아미드 화합물
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
BR122017023123B1 (pt) 2010-03-12 2018-04-24 Nippon Soda Co., Ltd. Método para produzir derivado de picolina halogenada
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
WO2012069428A1 (en) * 2010-11-22 2012-05-31 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
US9249157B2 (en) 2012-09-21 2016-02-02 Bristol-Myers Squibb Company Tricyclic heterocycle compounds
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
EP3554502A4 (en) 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
AU2020307471A1 (en) 2019-06-24 2022-01-27 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
NZ321293A (en) 1995-11-17 2001-04-27 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
CZ16899A3 (cs) 1996-07-22 1999-08-11 Monsanto Company Thiolsulfonamidové inhibitory metaloproteázy
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
JP2002535386A (ja) 1999-01-27 2002-10-22 アメリカン・サイアナミド・カンパニー アセチレンスルホンアミドチオールｔａｃｅインヒビター
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
ATE497186T1 (de) * 2001-12-14 2011-02-15 Raytheon Co Präzise justierte linsenstruktur und eine methode zur herstellung derselben
NZ533603A (en) 2001-12-20 2007-02-23 Bristol Myers Squibb Co Alpha-(N-sulphonamido)acetamide derivatives as beta-amyloid inhibitors used for treating Alzheimer's Disease and Down's syndrome
KR20040086465A (ko) * 2002-02-28 2004-10-08 아스트라제네카 아베 화합물
DE60313844T2 (de) * 2003-03-20 2008-01-31 Santhera Pharmaceuticals (Schweiz) Ag Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren
RU2342374C2 (ru) 2003-03-31 2008-12-27 Уайт Фтор- и трифторалкилсодержащие гетероциклические сульфонамидные ингибиторы образования бета-амилоида и их производные
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
PE20080169A1 (es) 2006-02-17 2008-04-11 Wyeth Corp Metodo para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
TW200732295A (en) 2006-02-17 2007-09-01 Wyeth Corp Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Also Published As

Publication number Publication date
EA201171439A1 (ru) 2012-05-30
CO6270332A2 (es) 2011-04-20
EP2205575A1 (en) 2010-07-14
SG174044A1 (en) 2011-09-29
EP2295417A1 (en) 2011-03-16
US20120088925A1 (en) 2012-04-12
KR20100075575A (ko) 2010-07-02
PT2295417E (pt) 2012-09-26
EA016447B1 (ru) 2012-05-30
HK1141801A1 (en) 2010-11-19
IL205406A0 (en) 2010-12-30
US20090111858A1 (en) 2009-04-30
SG174043A1 (en) 2011-09-29
EP2295417B1 (en) 2012-07-04
EA201000714A1 (ru) 2010-10-29
CN101910141B (zh) 2012-12-19
MX2010004319A (es) 2010-04-30
PL2205575T3 (pl) 2011-09-30
AR069135A1 (es) 2009-12-30
DK2205575T3 (da) 2011-07-11
HK1155161A1 (en) 2012-05-11
US8084477B2 (en) 2011-12-27
SI2205575T1 (sl) 2011-07-29
HRP20120703T1 (hr) 2012-09-30
CN102718689A (zh) 2012-10-10
US8350084B2 (en) 2013-01-08
CA2704360A1 (en) 2009-05-07
ATE502022T1 (de) 2011-04-15
CL2008003271A1 (es) 2009-07-10
TW200927099A (en) 2009-07-01
JP5460605B2 (ja) 2014-04-02
HRP20110219T1 (hr) 2011-04-30
NZ584545A (en) 2011-04-29
EP2471769A1 (en) 2012-07-04
PT2205575E (pt) 2011-05-23
ES2361283T3 (es) 2011-06-15
AU2008319122A1 (en) 2009-05-07
JP2011502153A (ja) 2011-01-20
BRPI0818837A2 (pt) 2015-04-22
WO2009058552A1 (en) 2009-05-07
PE20091394A1 (es) 2009-09-25
CN101910141A (zh) 2010-12-08
ES2390042T3 (es) 2012-11-06
DK2295417T3 (da) 2012-10-15
CY1112337T1 (el) 2015-12-09
CY1113346T1 (el) 2016-06-22
SI2295417T1 (sl) 2012-11-30
DE602008005636D1 (de) 2011-04-28
EP2205575B1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
PL2295417T3 (pl) Nowe produkty pośrednie przydatne do wytwarzania związku alfa-(n-sulfonamido)acetamidu
EP2152081A4 (en) NEW CONNECTIONS
EP2146745A4 (en) NOVEL CONNECTIONS
GB0705882D0 (en) Novel compounds
PL2074123T3 (pl) Nowe związki o działaniu przeciwlękowym
GB0706630D0 (en) Novel compounds
GB0705803D0 (en) Novel compounds
GB0710680D0 (en) Novel crystalline form of olmesartan medoxmil
ZA200806859B (en) Novel crystalline compounds
PL2173710T3 (pl) Nowa postać krystaliczna
GB0703973D0 (en) Novel compounds
IL195092A0 (en) Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate
HU0800755D0 (en) Novel crystalline forms
GB0806596D0 (en) Novel compounds A3
GB0707722D0 (en) Novel compounds A3
GB0608095D0 (en) Novel compounds A3
HK1157746A (en) 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors
GB0706030D0 (en) Novel compounds
GB0704324D0 (en) Novel compounds
GB0704012D0 (en) Novel compounds
GB0704766D0 (en) Novel compounds
GB0703631D0 (en) Novel compounds
GB0703630D0 (en) Novel compounds
GB0703404D0 (en) Novel compounds
GB0704088D0 (en) Novel compounds